Zyomyx Sells Protein Profiling Biochip System to Aventis

14-Mar-2003

Zyomyx, Inc., a leader in the development and commercialization of protein biochip technologies, today announced that Aventis has agreed to purchase Zyomyx' complete Protein Profiling Biochip System, featuring Zyomyx' first protein profiling biochip, the Human Cytokine Biochip. The Zyomyx system includes the Assay 1200(TM) automated workstation, the Scanner 100(TM) biochip reader and data analysis software. As part of Aventis' commitment to innovation, the company will apply the Protein Profiling Biochip System and Human Cytokine biochips to its research and development programs in inflammation. The Zyomyx Protein Profiling Biochip System has applications for industry researchers providing pivotal information in discovery, preclinical and clinical settings. "Zyomyx' protein analysis system has significant advantages over existing technologies. We are pleased that our Protein Profiling Biochip System and Human Cytokine Biochip have been selected by Aventis to further their internal research programs," said Lawrence Cohen, Ph.D., president and chief executive officer of Zyomyx. "Our Protein Profiling Biochip System has the ability to conduct highly multiplexed and comprehensive protein analysis - obtaining robust and accurate data using minimal samples. In essence, researchers will now have a data-rich snapshot of complex and quantitative protein expression patterns to inform drug discovery, preclinical and clinical evaluation, among other applications." The Zyomyx Protein Profiling Biochip System and the first of the company's biochips, the Human Cytokine Biochip, were launched in February, 2003. Aventis joins customers such as GlaxoSmithKline and Partners Healthcare in integrating Zyomyx' biochips and system into its research programs. Until recently, the productivity of research was limited by tools that could examine a small fraction of the proteins present in a sample at one time. Zyomyx' highly multiplexed, high-throughput system lifts the constraints on protein analysis, allowing scientists to engage in more productive and cost-effective protein research. The Protein Profiling Biochip System and Zyomyx' initial biochip offering, the Human Cytokine Biochip, enables researchers to profile the Expression of 30 human cytokines simultaneously and for the first time, using a wide variety of biological samples. This multiplexing capability will accelerate and transform research practices from early stages of drug discovery such as target validation, through preclinical and clinical applications, including patient population segregation and disease progression monitoring.

https://www.bionity.com/en/news/21475/zyomyx-sells-protein-profiling-biochip-system-to-aventis.html